This compound is an internally developed, selective, orally-bioavailable small molecule for the treatment of relapsed and refractory chronic myelogenous leukemia.
Mike Grey, CEO of SGX Pharmaceuticals, said: “Filing of this investigational new drug submission represents another testament to our internal capabilities. We continue to focus on moving our discovery and development programs forward.”